Drug Profile
Research programme: third-generation antifolates - Jacobus
Alternative Names: JPC 2005; JPS 2028; PS 15; PS 26; PS 33; Third-generation antifolates research programme - Jacobus; WR 250417Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Jacobus Pharmaceutical
- Developer Walter Reed Army Medical Center
- Class
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malaria; Mycobacterium avium complex infections; Pneumocystis pneumonia
Most Recent Events
- 16 Dec 2003 Preclinical trials in Malaria in USA (unspecified route)
- 16 Dec 2003 Data presented at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH-2003) have been added to the pharmacokinetics section
- 26 Jul 2001 No-Development-Reported for Malaria in USA (Unknown route)